A Comparison of Platelet Inhibition Following a Prasugrel 60 mg or Prasugrel 30 mg Loading Dose With or Without Pretreatment With a Clopidogrel Loading Dose in Acute Coronary Syndrome Patients Who Are to Undergo Percutaneous Coronary Intervention.

Trial Profile

A Comparison of Platelet Inhibition Following a Prasugrel 60 mg or Prasugrel 30 mg Loading Dose With or Without Pretreatment With a Clopidogrel Loading Dose in Acute Coronary Syndrome Patients Who Are to Undergo Percutaneous Coronary Intervention.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Prasugrel (Primary) ; Clopidogrel
  • Indications Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Pharmacodynamics
  • Acronyms TRIPLET
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 May 2012 Official Title amended as reported by Clinical Trials Registry - India record.
    • 19 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top